Appropriate use of hormones should alleviate concerns of cardiovascular and breast cancer risk

Maturitas

Volumn 51, Issue 1, 2005, Pages 98-109

  Lobo, Rogerio A ^a  

^a New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

Appropriate hormone use; Breast cancer risk; Cardiovascular risk; Hormone therapy

Indexed keywords

CALCIUM; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; GESTAGEN; HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEDROXYPROGESTERONE ACETATE; VITAMIN D;

AMENORRHEA; ATHEROSCLEROSIS; BRAIN ARTERY ANEURYSM; BREAST CANCER; BREAST TENDERNESS; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG USE; ENDOMETRIUM CANCER; ESTROGEN THERAPY; HEALTH HAZARD; HEART PROTECTION; HORMONAL THERAPY; HOT FLUSH; HUMAN; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; LUNG EMBOLISM; MASTALGIA; MENOPAUSAL SYNDROME; MENOPAUSE; MODEL; NERVOUS SYSTEM; OSTEOLYSIS; OSTEOPOROSIS; POPULATION RESEARCH; PRESCRIPTION; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; STROKE; SYMPTOM; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; UNITED STATES; UROGENITAL TRACT DISEASE; UTERUS; VAGINA BLEEDING;

ADULT; AGE FACTORS; AGED; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; UNITED STATES;

EID: 18844389194     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2005.02.020     Document Type: Conference Paper

References (80)

1. A.L. Hersh, M.L. Stefanick, and R.S. Stafford National use of post-menopausal hormone therapy: annual trends and response recent evidence JAMA 291 2004 47 53
2. F. Naftolin, H.S. Taylor, and R.K. Karas The Women's health initiative could not have detected cardioprotective effect of starting hormone therapy during the menopausal transition Fertil Steril 81 2004 1498 1501
3. S. Shapiro Effects of HRT on the risks of breast cancer and cardiovascular disease: the validity of the epidemiological evidence Gyn Obstet Fertil 32 2004 382 390
4. R.A. Lobo Observational studies and randomized clinical trials of hormone therapy: effect of stage of menopause on outcomes Schneider HPG F. Naftolin Climacteric medicine - where do we go? 2005 Taylor & Francis UK 154 159 [Chapter 20]
5. D.M. Herrington, E. Vittinghoff, and F. Lin Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement study (HERS) Circulation 105 25 2002 2962 2967
6. J.E. Manson, J. Hsia, and K.C. Johnson Estrogen plus progestin and the risk of coronary heart disease N Engl J Med 349 6 2003 523 534
7. R.T. Chlebowski, S.L. Hendrix, and R.D. Langer Influence of estrogen plus progestin on breast cancer and mammography in healthy post-menopausal women: the Women's Health Initiative Randomized Trial JAMA 289 24 2003 3243 3253
8. V. Beral Million women study collaborators. Breast cancer and hormone-replacement therapy in the Million Women study Lancet 362 9382 2003 419 427
9. W.D. Dupont, and D.L. Page Menopausal estrogen replacement therapy and breast cancer Arch Intern Med 151 1999 67 72
10. R.A. Lobo, and J.H. Pickar Evaluation of cardiovascular-event rates with hormone replacement therapy in healthy post-menopausal women Obstet Gynecol 101 2003 955
11. R.A. Lobo Evaluation of cardiovascular event rates with hormone therapy in healthy, early post-menopausal women: Results from two large clinical trials Arch Intern Med 164 2004 482 484
12. D. Zanger, B.K. Yang, and J. Ardans Divergent effects of hormone therapy on serum markers of inflammation in post-menopausal women with coronary artery disease on appropriate medical management J Am Coll Cardiol 36 2000 1797 1802
13. F. Grodstein, J.E. Manson, G.A. Colditz, W.C. Willett, F.E. Speizer, and M.J. Stampfer A prospective, observational study of post-menopausal hormone therapy and primary prevention of cardiovascular disease Ann Intern Med 133 2000 933 941
14. L. Speroff, R.T.W. Whitcomb, N.J. Kempfert, R.A. Boyd, J.B. Paulissen, and J.P. Rowan Efficacy and local tolerance of a low-dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms Obstet Gynecol 1996 587 592
15. W.H. Utian, D. Shoupe, G. Bachmann, J.V. Pinkerton, and J.H. Pickar Relief of vasomotor symptoms and vaginal atrophy with lower-doses of conjugated equine estrogens and medroxy-progesterone acetate Fertil Steril 75 2001 1065 1079
16. D. deAloysio, L.C. Rovati, G. Giamcovelli, I. Stenikar, and F. Bottiglioni Efficacy on climacteric symptoms and safety of low-dose estradiol transdermal matrix patches. A randomized, double-blind placebo-controlled study Drug Res 50 2000 293 300
17. I. Schiff The effects of progestins on vasomotor flushes J Reprod Med. 27 Suppl. 1982 498 502
18. J.P. Semmens, C.C. Tsai, E.C. Semmens, and C.B. Loadholt Effects of estrogen therapy on vaginal physiology during menopause Obstet Gynecol 66 1985 15 18
19. K. Nilsson, and G. Heimer Low-dose oestradiol in the treatment of urogenital estrogen deficiency - a pharmacokinetic and pharmacodynamic study Maturitas 15 1992 121 127
20. K.E. Nilsson, and G.M. Heimer Ultra-low-dose transdermal estrogen therapy in post-menopausal urogenital estrogen deficiency - a placebo-controlled study Menopause 1 1994 191 197
21. L. Henriksson, M. Stjernquist, L. Boquist, I. Cedergren, and I. Selinus A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in post-menopausal women with symptoms and signs of urogenital aging Am J Obstet Gynecol 174 1996 85 92
22. M. Notelovitz Urogenital atrophy and low-dose vaginal estrogen therapy Menopause 7 2000 140 142
23. S.R. Cummings, W.S. Browner, and D. Bauer Endogenous hormones and the risk of hip and vertebral fractures among older women N Engl J Med 339 1998 733 738
24. B. Ettinger, A. Pressman, P. Sklarin, D.C. Bauer, J.A. Cauley, and S.R. Cummings Associations between low levels of serum estradiol, bone density, and fractures J Clin Endocrinol Metab 83 1998 2239 2243
25. J.Y. Reginster, N. Sarlet, R. Deroisy, A. Albert, U. Gaspard, and P. Franchimont Minimal levels of serum estradiol prevent post-menopausal bone loss Calcif Tissue Int 51 1992 340 343
26. J.A. Cauley, D.G. Seeley, and K. Ensrud Estrogen replacement therapy and fractures in older women Ann Intern Med. 122 1995 9 16
27. F.W. Lafferty, and M.E. Fiske Post-menopausal estrogen replacement: a long-term cohort study Am J Med 97 1994 66 77
28. D.L. Schneider, E.L. Barrett-Connor, and D.J. Morton Timing of post-menopausal estrogen for optimal bone mineral density. The Rancho Bernardo study J Am Med Assoc 277 1997 543 547
29. L. Speroff, J. Rowan, J. Symons, H. Genant, and W. Wilborn For the CHART study group. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). A randomized controlled trial J Am Med Assoc 276 1996 1397 1403
30. B. Ettinger, H.K. Genant, and C.E. Cann Post-menopausal bone loss is prevented by treatment with low-dosage estrogen with calcium Ann Intern Med 106 1987 40 45
31. H.K. Genant, J. Lucas, and S. Weiss Low-dose esterified estrogen therapy. Effects on bone, plasma estradiol concentrations, endometrium, and lipid levels Arch Intern Med 157 1997 2609 2614
32. S.F. Evans, and M.W.J. Davie Low and conventional dose transdermal oestradiol are equally effective at preventing bone loss in spine and femur at all post-menopausal ages Clin Endocrinol 44 1996 79 84
33. H. Mizunuma, H. Okano, and M. Soda Prevention of post-menopausal bone loss with minimal uterine bleeding using low-dose continuous estrogen/progestin therapy: a 2-year prospective study Maturitas 27 1997 69 76
34. R.R. Recker, K.M. Davies, R.M. Dowd, and R.P. Heaney The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women: a randomized, controlled trial Ann Intern Med 130 1999 897 904
35. J.C. Gallagher, W.T. Kable, and E. Goldgar Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen Am J Med 90 1991 171 178
36. G.A. Greendale, M. Espeland, S. Slone, R. Marcus, and E. Barrett-Connor PEPI Safety Follow-Up study (PSFS) Investigators. Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Post-menopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up study Arch Intern Med 162 2002 665 672
37. K.Y. Leung, T.K. Lee, C.N. Lee, T.K. Sum, M.Y.M. Chan, and C.M. Ton The effects of different dosages of estrogen on the bone mineral density of post-menopausal Hong Kong Chinese women: randomized controlled trial Hong Kong Med J 5 1999 9 14
38. K.M. Prestwood, A.M. Kenny, A. Kleppinger, and M. Kulldorff Ultra-low-dose micronized 17β estradiol and bone density and bone metabolism in older women JAMA 290 2003 1042 1048
39. B. Ettinger, K.E. Ensrud, and R. Wallace Effects of ultra-low-dose transdermal estradiol on bone mineral density: a randomized clinical trial Obstet Gynecol 104 3 2004 443 451
40. American Heart Association. 2000. Heart and stroke statistical update. Dallas, TX, American Heart Association. 1999; 1-29.
41. W.B. Kannel, and PW.F. Wilson Risk factors that attenuate the female coronary disease advantage Arch Intern Med. 155 1995 57 61
42. F. Grodstein, M.J. Stampfer, and J. Manson Post-menopausal estrogen and progestin use and the risk of cardiovascular disease N Engl J Med 335 1996 453 461
43. D. Grady, S.M. Rubin, and D.B. Petitti Hormone therapy to prevent disease and prolong life in post-menopausal women Ann Intern Med 117 1992 1016 1037
44. E. Barrett-Connor, and D. Grady Hormone replacement therapy, heart disease, and other considerations Annu Rev Public Health 19 1998 55 72
45. M.E. Mendelsohn, and R.H. Karas The protective effects of estrogen on the cardiovascular system N Eng J Med 340 1999 1801 1811
46. C.H. Selzman, T.A. Whitehill, B.D. Shames, E.J. Pulido, B.C. Cain, and A.H. Harken The biology of estrogen-mediated repair of cardiovascular injury Ann Thorac Surg 65 1998 868 874
47. Writing group for the PEPI trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in post-menopausal women. The Post-menopausal Estrogen/Progestin Interventions (PEPI) trial. J Am Med Assoc 1995; 273:199-208.
48. B.M. Wolfe, and M.W. Huff Effects of continuous low-dose hormonal replacement therapy on lipoprotein metabolism in post-menopausal women Metabolism 44 1995 410 417
49. M.A. Espeland, S.M. Marcovina, and V. Miller Effect of post-menopausal hormone replacement therapy on lipoprotein (a) concentration Circulation 97 1998 979 986
50. W. Schlegel, L.I. Petersdorf, R. Junker, H. Schulte, C. Ebert, and von Eckardstein The effects of six months of treatment with a low-dose of conjugated estrogens in menopausal women Clin Endocrinol (Oxf) 51 1999 643 651
51. R.A. Lobo, T. Bush, B.R. Carr, and J.H. Pickar Efects of lower-doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism Fertil Steril 76 2001 13 24
52. F. Leonardo, F. Pelliccia, and G. Mercuro Effect of low and standard dose of estrogen replacement therapy upon endothelial function in menopausal women at risk of coronary events (Abstr) J Am Coll Cardiol 35 Suppl. A 2000 247A
53. M. Sanada, Y. Higashi, and K. Nakagawa A comparison of low-dose and standard-dose oral estrogen on forearm endothelial function in early post-menopausal women J Clin Endocrinol Metab 88 2003 1303 1309
54. G. Mercuro, C. Vitale, M. Fini, S. Zoncu, F. Leonardo, and G. Rosano Lipid profiles and endothelial function with low-dose hormone replacement therapy in post-menopausal women at risk for coronary artery disease: a randomized trial Inter J Cardio 108 2003 808 813
55. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. 1996; 348, 977-80.
56. H. Jick, L.E. Derby, M.W. Myers, C. Vasilakis, and K.M. Newon Risk of hospital admission for idiopathic venous thromboembolism among users of post-menopausal estrogens Lancet 348 1996 981 983
57. S.M. Phillips, and B.B. Sherwin Effects of estrogen on memory function in surgically menopausal women Psychoneuroendocrinology 17 1992 485 495
58. B.B. Sherwin Estrogenic effects on memory in women Ann NY Acad Sci 743 1994 213 231
59. T. Thomas, J.A. Rhodin, E.T. Sutton, M.W. Bryant, and J.M. Price Estrogen protects peripheral and cerebral blood vessels from toxicity of Alzheimer peptide amyloid-beta and inflammatory reaction J Submicrosc Cytol Pathol 31 1999 571 579
60. T. Thomas, and J. Rhodin Vascular actions of estrogen and Alzheimer's disease Ann NY Acad. Sci 903 2000 501 509
61. R.C. Miranda, F. Sohrabji, and C.D. Toran-Allerand Presumptive estrogen target neurons express mRNAs for both the neurotrophins and neurotrophin receptors: a basis for potential developmental interactions of estrogen with the neurotrophins Mol Cell Neurosci 4 1993 510 525
62. C.D. Toran-Allerand, M. Singh, and G. Setalo Jr. Novel mechanisms of estrogen action in the brain: new players in an old story Front Neuroendocrinol 20 1999 97 121
63. A.R. Genazzani, A. Spinetti, R. Gallo, and F. Bernardi Menopause and the central nervous system: intervention options Maturitas 31 1999 103 110
64. B.B. Sherwin Estrogen and cognitive functioning in women Proc Soc Exp Biol Med 217 1998 17 22
65. D.L. Kampen, and B.B. Sherwin Estrogen use and verbal memory in healthy post-menopausal women Obstet Gynecol 83 1994 979 983
66. P. Lopez-Jaramillo, and E. Teran Improvement in functions of the central nervous system by estrogen replacement therapy might be related with an increased nitric oxide production Endothelium 6 1999 263 266
67. J.F. Trabal, J.P. Lenihan Jr., and T.E. Melchione Low-dose unopposed estrogens: preliminary findings on the frequency and duration of vaginal bleeding in post-menopausal women receiving esterified estrogens over a two-year period Menopause 4 1997 130 138
68. A.H. MacLennan, A. MacLennan, S. Wenzel, H.M. Chambers, and K. Eckert Continuous low-dose estrogen and progestogen hormone replacement therapy: a randomized trial Med J Aust 159 1993 102 106
69. D.F. Archer, M. Dorin, V. Lewis, D.L. Schneider, and J.H. Pickar Effects of lower-doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding Fertil Steril 75 6 2001 1080 1087
70. L. Speroff, R.W. Witcomb, N.J. Kempfert, R.A. Boyd, J.B. Paulissen, and J.P. Rowan Efficacy and local tolerance of a low-dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms Obstet Gynecol 88 1996 587 592
71. C. Cooper, J.A. Stakkestad, and S. Radowicki Matrix delivery transdermal 17 β-estradiol for the prevention of bone loss in post-menopausal women Osteoporosis Int 9 1999 356 358
72. M. Notelovitz, R.E. Varner, and R.W. Rebar Minimal endometrial proliferation over a two-year period in post-menopausal women taking 0.3 mg of unopposed esterified estrogens Menopause 4 1997 80 88
73. K.L. Cushing, N.S. Weiss, L.F. Voigt, B. McKnight, and S.A. Beresford Risk of endometrial cancer in relation to use of low-dose unopposed estrogens Obstet Gynecol 91 1998 35 39
74. D. Grady, T. Gebretsadik, K. Kerlikowske, V. Ernster, and D. Petitti Hormone replacement therapy and endometrial cancer risk: a meta-analysis Obstet Gynecol 85 1995 304 313
75. E. Weiderpas, J.A. Baaron, and H.O. Adami Low-potency estrogen and risk of endometrial cancer: a case-control study Lancet 353 1999 1824 1828
76. I.H. Suparto, J.K. Williams, J.M. Cline, M.S. Anthony, and J.L. Fox Contrasting effects of two hormone replacement therapies on the cardiovascular and mammary gland outcomes in surgically post-menopausal monkeys Am J Ob Gyn 188 5 2003 1132 1140
77. P.Y. Scarabin, E. Oger, and G Plu-Bureau Estrogen and ThromboEmbolism Risk study group. Differential association of oral and transdermal estrogen-replacement therapy with venous thromboembolism risk Lancet 362 2003 428 432
78. R.A. Lobo, D.F. Archer, and B. Ettinger Role of progestogen in hormone therapy for post-menopausal women: position statement of the North American Menopause Society Menopause 10 2003 113 132
79. M. Cushman, L.H. Kuller, and R. Prentice Women's Health Initiative Investigators JAMA 292 13 2004 1573 1580
80. J.L. Turgeon, D.P. McDonnell, K.A. Martin, and P.M. Wise Hormone therapy: physiological complexity belies therapeutic simplicity Science 304 5675 2004 1269 1273